Oculis Holding AG 是一家全球性的生物制药公司,致力于改善视力和眼科护理。公司总部位于瑞士楚格,在全球范围内拥有49名全职员工,并于2023年3月3日完成首次公开募股。该公司专注于眼科疾病治疗的研发。其产品包括:基于OPTIREACH技术的局部视网膜候选药物OCS-01,用于治疗糖尿病性黄斑水肿(DME);以单链抗体片段形式存在的局部生物制剂候选药物OCS-02,用于治疗干眼病(DED);以及用于急性视神经炎(AON)及其他神经眼科疾病(如青光眼、糖尿病视网膜病变、地理萎缩和神经营养性角膜炎)的疾病修饰候选药物OCS-05。公司业务覆盖美国、欧洲和中国,Ocullis为全球患者提供治疗方案。
The most recent EPS for Oculis Holding AG is $-0.16, 未达预期 expectations of $-0.4.
How did Oculis Holding AG OCS's revenue perform in the last quarter?
Oculis Holding AG revenue for the last quarter is $-0.16
What is the revenue estimate for Oculis Holding AG?
According to 9 of Wall street analyst, the revenue estimate of Oculis Holding AG range from $315.0K to $0.0
What's the earning quality score for Oculis Holding AG?
Oculis Holding AG has a earning quality score of B/34.018967. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Oculis Holding AG report earnings?
Oculis Holding AG next earnings report is expected in 2026-11-04
What are Oculis Holding AG's expected earnings?
Oculis Holding AG expected earnings is $148.62K, according to wall-street analysts.
Did Oculis Holding AG beat earnings expectations?
Oculis Holding AG recent earnings of $310.0K 超出预期 expectations.